Study at a glance
Which enzymes help make and remove active vitamin D?
This page summarises evidence about two enzymes, proteins that help chemical reactions occur. CYP27B1 helps make active vitamin D, while CYP24A1 helps process forms of vitamin D for removal. The review brings together laboratory experiments, genetically modified mice, human genetic disorders and hormone studies. These are different sources of evidence, not one study population.
How do these enzymes control the supply of active vitamin D?
CYP27B1 changes 25-hydroxyvitamin D into calcitriol, the main active vitamin D hormone. CYP24A1 processes both the earlier form and calcitriol through several steps, limiting how much remains available and for how long. Hormones coordinate these processes in the kidneys. Parathyroid hormone usually favours production, while FGF23 and calcitriol itself favour less active vitamin D being available.
What happened when vitamin D-processing enzymes were changed or missing?
Changes to the structure of CYP24A1 changed which products it made in laboratory tests. In mice completely lacking this enzyme, the time for blood calcitriol to fall by half increased from about 6 to 60 hours. Human genetic disorders also show the importance of these enzymes: severe failure of activation or removal can disturb calcium control. The mouse timing result is not an estimate for ordinary human differences.
Does vitamin D processing always make it inactive straight away?
Finding an activating enzyme outside the kidneys does not prove that the tissue supplies much active vitamin D to the blood. CYP24A1 is a major processing route, but other enzymes can contribute. Processing also occurs in stages, and not every substance made along the way becomes inactive straight away. Results from different species and methods must keep their separate limits.
Read the full article below ↓CYP27B1 and CYP24A1 control opposite sides of active vitamin D metabolism. The review by Jones, Prosser and Kaufmann brings together biochemical, structural, genetic and physiological evidence showing how CYP27B1 forms calcitriol from 25-hydroxyvitamin D, while CYP24A1 progressively metabolises both precursor and active hormone. The key idea is not simply “activation versus destruction,” but a regulated balance between formation, local use, feedback and clearance.
What question does the review help answer?
The review examines the cytochrome P450 enzymes involved in vitamin D metabolism, within the broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) framework. For the CYP27B1/CYP24A1 pathway, it explains which enzyme performs the decisive 1α-hydroxylation step, how CYP24A1 routes vitamin D metabolites through C24: and C23-initiated pathways, how enzyme structure changes product distribution, and how genetics and endocrine feedback reveal the physiological importance of those reactions.
Because it is a review rather than a single experiment, its evidence comes from multiple models and methods. Recombinant-enzyme studies establish catalytic capacity; mutagenesis links protein structure to product choice; knockout mice test physiological necessity; human mutations reveal disease consequences; and endocrine studies show how the kidney adjusts activation and catabolism in opposite directions.
How does CYP27B1 activate vitamin D?
CYP27B1 is the established 25-hydroxyvitamin D 1α-hydroxylase. It converts 25(OH)D to 1,25(OH)2D, or calcitriol, the high-affinity hormonal ligand for VDR. Human CYP27B1 loss-of-function causes vitamin-D-dependent rickets type 1A, showing that adequate precursor cannot compensate for severe failure of the activation step.
CYP27B1 is a mitochondrial P450 enzyme. Its reaction depends on mitochondrial electron transfer through redox partners as well as on substrate availability. The kidney is the principal regulated source of circulating calcitriol, while extra-renal CYP27B1 commonly supports more local intracrine or paracrine signalling.
How does CYP24A1 reduce vitamin D exposure?
CYP24A1 can metabolise both 25(OH)D and calcitriol. It can therefore reduce substrate available for later activation and shorten active-hormone exposure after calcitriol has formed.
The enzyme is not limited to one 24-hydroxylation step. It can initiate C24 and C23 oxidation routes and then perform further side-chain oxidations. These pathways lead toward different downstream metabolites, including calcitroic-acid and lactone-related products. This is progressive catabolism rather than an instantaneous molecular off switch.
What do structure and genetics add to the picture?
Active-site mutagenesis shows that CYP24A1 product routing depends on substrate orientation inside the enzyme. Wild-type rat CYP24A1 showed a C24:C23 ratio of roughly 100:1 in a cited series. Individual substitutions shifted that ratio to about 12.5:1 and 6.3:1, compared with about 3.7:1 for human CYP24A1. Small structural changes can therefore redirect metabolic flux substantially.
The physiological effect of CYP24A1 loss is equally striking. In Cyp24a1-null mice, calcitriol plasma half-life increased from roughly 6 hours to roughly 60 hours. Human loss-of-function variants are also associated with idiopathic infantile hypercalcaemia and related hypercalcaemic phenotypes. Together, these findings show that CYP24A1 is a major determinant of vitamin D metabolite persistence.
How are activation and catabolism coordinated?
Renal regulation moves CYP27B1 and CYP24A1 in reciprocal directions. PTH generally favours calcitriol production; FGF23 favours lower active-hormone availability; and calcitriol feeds back by suppressing CYP27B1 while strongly inducing CYP24A1. Production and removal therefore respond together rather than behaving as independent reactions.
CYP24A1 remains the specialised central catabolic enzyme, but it is not literally the only oxidative route in every tissue. CYP3A4 can also metabolise vitamin D compounds, especially in liver, intestine and inducible exposure settings.
What should not be concluded from this evidence?
The quantitative results come from different experimental systems, so rat product ratios, mouse knockout half-lives and human disease phenotypes should not be treated as if they were measurements from one study population. Extra-renal expression does not prove a major contribution to circulating calcitriol, complete gene knockout does not predict the effect size of ordinary variation, and the existence of some biologically active downstream metabolites does not overturn CYP24A1’s dominant catabolic role.
The most secure conclusion is that CYP27B1 creates the principal active vitamin D hormone and CYP24A1 is central to limiting precursor and active-hormone exposure through regulated multistep metabolism.
Primary source and further reading
Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research. 2014;55(1):13 to 31. PMID 23564710; PMCID PMC3927478; DOI 10.1194/jlr.R031534.
Read the full Jones, Prosser and Kaufmann paper. For the deeper structural, genetic and physiological treatment, read the Full Evidence Review.
Related reading
Molecular Analysis of CYP27B1 Mutations in Vitamin D-Dependent Rickets Type 1A: c.590G > A (p.G197D) Missense Mutation Causes a RNA Splicing Error
Twelve patients from 7 Turkish and 2 Saudi families were investigated.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Roles of CYP27B1 and CYP24A1 in activation and inactivation: Full Study Summary
Explore how CYP27B1 activates vitamin D and CYP24A1 controls its inactivation, metabolism and clearance, with biochemical, genetic and physiological evidence.SLUG:cyp27b1-cyp24a1-activation-inactivation-full-evidence-review.
Read more →Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1)
Vitamin D enzyme pathways regulate how vitamin D is activated and broken down in the body.
Read more →Combined Treatment with Omega-3 Fatty Acid and Cholecalciferol Increases 1,25-Dihydroxyvitamin D Levels by Modulating Dysregulation of Vitamin D Metabolism in 5/6 Nephrectomy Rats
The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats.
Original paper ↗Read more →Loss of 24-hydroxylated catabolism increases calcitriol and fibroblast growth factor 23 and alters calcium and phosphate metabolism in fetal mice
The null fetuses were hypercalcemic, modestly hypophosphatemic (compared to Cyp24a1+/− fetuses only), with 3.5-fold increased calcitriol, 4-fold increased fibroblast growth factor 23 (FGF23), and unchanged parathyroid hormone.
Original paper ↗Read more →Association between 25-Hydroxyvitamin D, Parathyroid Hormone, Vitamin D and Calcium Intake, and Bone Density in Healthy Adult Women: A Cross-Sectional Analysis from the D-SOL Study
This cross-sectional analysis aimed to investigate the associations of 25(OH)D and plasma PTH concentrations with bone parameters, and potential confounders, in women living in a high (England) or low (Brazil) latitude country.
Original paper ↗Read more →Associations of Vitamin D Deficiency, Parathyroid hormone, Calcium, and Phosphorus with Perinatal Adverse Outcomes. A Prospective Cohort Study
We aimed to evaluate the association of vitamin D deficiency during early pregnancy with preterm birth.
Original paper ↗Read more →Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis
However, evidence of the causal role of mineral metabolism in CAVS is still lacking.
Original paper ↗Read more →Interactions between Vitamin D Status, Calcium Intake and Parathyroid Hormone Concentrations in Healthy White-Skinned Pregnant Women at Northern Latitude
Little explored in pregnancy, we aimed to examine the relative importance of serum 25-hydroxyvitamin D (25(OH)D) and calcium intake on parathyroid hormone (PTH) concentrations in healthy white-skinned pregnant women.
Original paper ↗Read more →Postprandial metabolic responses of serum calcium, parathyroid hormone and C-telopeptide of type I collagen to three doses of calcium delivered in milk
The present study investigated Ca absorption patterns with increasing levels of fortification in milk, and the response to one dose of a Ca salt.
Original paper ↗Read more →R990G Polymorphism of Calcium Sensing Receptor Gene Is Associated with High Parathyroid Hormone Levels in Subjects with Vitamin D Deficiency: A Cross-Sectional Study
Single nucleotide polymorphisms (SNPs), R990G and A986S of the calcium sensing receptor (CaSR) gene, are shown to influence response of parathyroid hormone (PTH) in subjects with optimal vitamin D levels.
Original paper ↗Read more →The Role of Calcium, 25-Hydroxyvitamin D, and Parathyroid Hormone in Irritable Bowel Syndrome: A Bidirectional Two-Sample Mendelian Randomization Study
Therefore, we aimed to explore the bidirectional causal effects among serum calcium, Vit-D, PTH, and IBS at the genetic level by a two-sample Mendelian randomization (MR) analysis of the datasets from IEU OpenGWAS database.
Original paper ↗Read more →Vitamin D Status among Thai School Children and the Association with 1,25-Dihydroxyvitamin D and Parathyroid Hormone Levels
Only 4% (21 of 529) participants had a serum 25(OH)D level below 50 nmol/L.
Original paper ↗Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study
Explore why 25(OH)D reflects vitamin D status while 1,25(OH)₂D is a tightly regulated active hormone, including PTH, FGF23 and renal control.
Read more →Common Variation in Vitamin D Pathway Genes Predicts Circulating 25-Hydroxyvitamin D Levels among African Americans
Vitamin D is implicated in a wide range of health outcomes, and although environmental predictors of vitamin D levels are known, the genetic drivers of vitamin D status remain to be clarified.
Original paper ↗Read more →Elevated Serum 25-Hydroxyvitamin D Levels Are Associated with Improved Bone Formation and Micro-Structural Measures in Elderly Hip Fracture Patients
We have investigated whether varying vitamin D status in humans, as measured by serum 25(OH)D levels, relate to micro-structural and histomorphetric measures of bone quality and quantity, rather than density.
Original paper ↗Read more →Relationship Between Total 25-Hydroxyvitamin D and Parathyroid Hormone Concentrations During Early Gestation in Indian Women
The inverse relationship between 25(OH)D and parathyroid hormone (PTH) concentrations was examined to define the breakpoint at which PTH was maximally suppressed using a segmented regression analysis.
Original paper ↗Read more →Serum 25-hydroxyvitamin D and parathyroid hormone in relation to plasma B-type natriuretic peptide: the Hoorn Study
Therefore, we investigated whether lower 25-hydroxyvitamin D (25(OH)D) and higher PTH are cross sectionally and after 8 years of follow-up associated with higher B-type natriuretic peptide (BNP) levels in older men and women.
Original paper ↗Read more →Original sources
Read the full Jones, Prosser and Kaufmann paper
Read the full Jones, Prosser and Kaufmann paper.
Publication details
Read the full Jones, Prosser and Kaufmann paper. For the deeper structural, genetic and physiological treatment, read the Full Evidence Review.